8K+ Clinical Ops Decision-Makers. 7K Monthly Searches. Who's Reaching Them?
Your ICP is searching for CRO partners and evaluating options. Here's where the demand is.
Key Findings
8K+ VP/Director Clinical Operations on LinkedIn in biotech & pharma - your core buyer audience across US, UK, and EU.
7,000+ monthly searches for CRO/clinical trial services - $15-30 CPCs signal enterprise buyers actively evaluating partners.
"Decentralized clinical trials" is greenfield - 590/mo searches, competitors own "CRO" but Lindus can own the DCT/hybrid narrative.
1,300
Branded Searches/Mo
4,400
Category Searches/Mo
$15-30
Avg. CPC Range
72.9%
Your Speed Advantage
Search Demand Analysis
| Keyword | Type | Volume/Mo | CPC |
|---|---|---|---|
| lindus health | Branded | 1,300 | $14.84 |
| clinical research organization | Category | 4,400 | $15.14 |
| contract research organization | Category | 4,400 | $15.14 |
| patient recruitment clinical trials | High Intent | 720 | $30.35 |
| decentralized clinical trials | High Intent | 590 | $14.87 |
| phase 2 clinical trial | Category | 880 | $6.24 |
| phase 3 clinical trial | Category | 1,300 | $9.25 |
Competitive Landscape
The CRO market is dominated by legacy players (IQVIA, ICON, PPD, PAREXEL, Syneos Health) who compete on scale and global reach. Lindus Health's "Anti-CRO" positioning creates a distinct category opportunity:
- Speed narrative: 72.9% faster trials is a quantifiable differentiator in a market where timeline overruns are the #1 complaint
- Fixed-price model: Performance-based pricing addresses the #2 complaint (cost overruns)
- DCT/Hybrid positioning: "Decentralized clinical trials" has 590 monthly searches with lower CPCs - Lindus can own this emerging category before incumbents
- Citrus platform: Proprietary eClinical tech differentiates from CROs that cobble together third-party tools
The Demand Opportunity
Post-Series B ($55M), Lindus is positioned to capture demand at scale. The question is: who's reaching these buyers first?
- LinkedIn: 8K+ VP/Director Clinical Ops + R&D leaders in biotech/pharma - highly targetable by company size, therapeutic area, and geography
- Search: 7K+ monthly searches across category and high-intent terms - competitors are bidding $15-30/click, indicating serious enterprise buyers
- Content gap: No one owns the "anti-CRO" or "faster trials" narrative in paid - this is white space
Want the Full Demand Landscape?
This briefing covers the opportunity. The full strategy maps demand to channels, identifies quick wins, and includes a 90-day execution roadmap tailored for the new brand launch.
15 minutes. We'll walk through the numbers.